Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Haemophilus influenzae type B
2022
2019
Western Pacific
Clear all
Type of publications
NITAG documentation
(11)
Systematic reviews (SYSVAC)
(7)
Topics
Available to download in languages
Regions
Western Pacific
(18)
Africa
(28)
Americas
(41)
Eastern Mediterranean
(3)
Europe
(34)
South-East Asia
(2)
Countries
Australia
(11)
China
(6)
Diseases
COVID-19
(17)
Haemophilus influenzae type B
(1)
Diphtheria
(1)
Hepatitis B
(4)
Human papillomavirus (HPV)
(5)
Influenza
(3)
Japanese encephalitis
(1)
Meningococcal disease
(1)
Mpox // Monkeypox
(1)
Pertussis
(1)
Pneumococcal disease
(4)
Poliomyelitis
(1)
Tetanus
(1)
Tuberculosis
(1)
Vaccine topics
Acceptance
(3)
Administration
(1)
Economic aspects
(1)
Efficacy/effectiveness
(2)
Safety
(2)
Target population
Adolescents
(2)
Adults
(5)
All age groups
(1)
Children
(3)
Healthcare workers
(1)
Newborn
(1)
Older adults
(2)
Parents/caregivers
(1)
Publication date
2022
(17)
2019
(1)
2023
(5)
2021
(14)
2020
(19)
2017
(1)
2015
(1)
2013
(2)
18 results found
2022
∙
ATAGI
Novavax vaccine for adolescents aged 12-17 years
2022
∙
ATAGI
ATAGI recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years
2022
∙
ATAGI
ATAGI recommendations on the use of a booster dose of COVID-19 vaccine
2022
∙
ATAGI
ATAGI statement on defining 'up-to-date' status for COVID-19 vaccination
2022
∙
ATAGI
ATAGI statement on recommendations on a winter booster dose of COVID-19 vaccine
2022
∙
ATAGI
ATAGI updated recommendations for a winter dose of COVID-19 vaccine
2022
∙
ATAGI
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
2019
∙
Dolhain, J. Janssens, W. Sohn, W. Y. Dindore, V. Mukherjee, P.
Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register